Amgen v. Celltrion: 29-Patent Denosumab Biosimilar Battle Ends in Consent Judgment
Amgen filed suit against Celltrion in the District of New Jersey asserting 29 patents covering its blockbuster bone-loss biologics Prolia® and XGEVA® (denosumab). The case closed 310 days after filing via Consent Judgment — a resolution structure that typically signals a negotiated market-entry agreement between the parties.
Amgen’s 29-Patent Denosumab Fortress Meets Celltrion Biosimilar Entry
Filed on 28 May 2024 in the District of New Jersey, this case is a classic Biologics Price Competition and Innovation Act (BPCIA) infringement action. Amgen, Inc. and its manufacturing affiliate asserted 29 US patents against Celltrion, Inc. and Celltrion USA, Inc. covering virtually every layer of the denosumab product lifecycle — from antibody composition and cell culture processes to formulation and purification — with the commercial products at stake being Prolia® and XGEVA®, two high-value RANK-L inhibitors used in osteoporosis and oncology bone-disease indications.
The case terminated on 3 April 2025 via Consent Judgment — a court-entered resolution reflecting an agreement between the parties rather than a contested adjudication on the merits. Consent judgments in BPCIA litigation typically accompany a settlement that includes a negotiated biosimilar launch date, licensing terms, or both. The specific commercial terms are not disclosed in the public docket, and the scope of any launch rights granted to Celltrion remains unknown from available records.
The 310-day duration is relatively compact for a dispute of this patent count and complexity, suggesting the parties reached commercial alignment without protracted claim construction or trial preparation. The volume of supplementary submissions noted in the verdict text — including an active confidentiality order dispute — indicates the case was vigorously contested before settlement momentum built. What drove final resolution, including whether a launch date was agreed, is not evident from the public record.
Filing to Consent Judgment in 310 days
310 days — faster than the median BPCIA biosimilar litigation in the D.N.J.
Consent Judgment: what this resolution means for each party
Consent Judgment is not a win or loss — it is a negotiated endpoint
A Consent Judgment is a court-entered order reflecting terms agreed by both parties. It closes the litigation without a merits ruling on infringement or validity. In BPCIA biosimilar cases, it almost always accompanies a private settlement agreement specifying when and how the biosimilar may enter the market. The judgment provides finality and judicial enforceability without public disclosure of commercial terms.
No merits adjudicationAmgen retains enforcement leverage; 29 patents remain valid on the public record
Because the case closed without a validity or infringement ruling, all 29 asserted patents remain formally unchallenged in this proceeding. Amgen likely secured a degree of market exclusivity protection — the primary objective in BPCIA suits. Any agreed launch date would represent a commercial concession from Amgen, but its patent portfolio is not publicly weakened. Amgen retains the right to assert these patents against other biosimilar filers.
Portfolio intactCelltrion avoids patent invalidation risk; launch pathway likely secured
By settling, Celltrion avoids the risk of an injunction or an adverse infringement ruling that could have blocked US market entry entirely. Consent Judgments in this context typically grant the biosimilar developer a defined launch window — either a specific date or event-triggered authorization. Celltrion did not achieve a public patent invalidity finding, which means it cannot rely on this case to clear the patent landscape for future products.
Likely negotiated entry dateDenosumab biosimilar market entry timeline remains commercially sensitive
Prolia® and XGEVA® together represent multi-billion-dollar annual revenue for Amgen. Any Celltrion launch authorized under a consent judgment will mark the beginning of biosimilar price competition in this space. Other denosumab biosimilar applicants — not party to this consent judgment — remain subject to the full force of Amgen’s 29-patent portfolio. This settlement may signal Amgen’s preferred strategy of negotiated entry over protracted litigation across all biosimilar challengers.
Biosimilar market watchFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Amgen, Inc. | Company | Biopharmaceutical innovator — holder of 29 denosumab patents including US11459595B2Search in Eureka ↗ |
| Co-Plaintiff | AMGEN MANUFACTURING LIMITED LLC | Company | Search in Eureka ↗ |
| Defendant | Celltrion, Inc. | Company | Celltrion, Inc. and Celltrion USA, Inc. — South Korean biosimilar developer and US commercial arm seeking denosumab market entry.Search in Eureka ↗ |
| Co-Defendant | CELLTRION USA, INC. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Jessica K. Formichella | Attorney | Counsel for Amgen, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for Amgen, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Marc D. Haefner | Attorney | Counsel for Amgen, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’Reilly Falanga LLP | Law Firm | Representing Amgen, Inc.Search in Eureka ↗ |
| Defendant counsel | James S. Richter | Attorney | Counsel for Celltrion, Inc.Search in Eureka ↗ |
| Defendant law firm | MIDLIGE RICHTER LLC | Law Firm | Representing Celltrion, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The verdict text centers on a procedural confidentiality order dispute, not a substantive infringement ruling — consistent with a case that resolved commercially before merits adjudication. The volume of supplementary submissions (ECF Nos. 195–358) reflects active pre-settlement motion practice. The case’s termination by Consent Judgment means no finding on infringement or patent validity was made. The public record is silent on licensing terms, launch dates, or royalty arrangements, which is standard for BPCIA settlements where commercial terms are protected by separate confidential agreements.
US11459595B2 and 28 further denosumab patents — antibody, process & formulation IP
The 29 asserted patents collectively cover the full denosumab product stack: antibody composition (including anti-RANK-L binding sequences), upstream cell culture and manufacturing processes, downstream purification and chromatography methods, and final drug formulation and dosing. Patents span application dates from the early 2000s through the 2020s, reflecting a multigenerational prosecution strategy that has layered new protections as Amgen refined its manufacturing platform for Prolia® and XGEVA®.
From a competitive intelligence standpoint, this portfolio represents one of the most extensive patent thickets in the US monoclonal antibody biosimilar space. Any entity seeking to commercialize a denosumab biosimilar in the US must navigate not only composition-of-matter claims but also process and formulation patents that may cover the most commercially viable production routes. The portfolio’s breadth — spanning 29 patents across multiple technology layers — substantially raises the cost and risk of successful biosimilar entry without a negotiated license.
Should you run an FTO against Amgen’s denosumab patent portfolio?
Any company developing, manufacturing, or investing in a denosumab biosimilar — including those with aBLA filings pending or in preparation — should treat this 29-patent portfolio as a primary FTO priority. The patents cover not just the antibody molecule itself but process and formulation methods that are difficult to design around without significant manufacturing changes. Celltrion’s consent judgment provides no freedom-to-operate benefit to other applicants.
PatSnap Eureka’s FTO Search Agent can map each of the 29 asserted patent families against your biosimilar’s manufacturing process, formulation route, and cell culture platform — identifying which claim sets pose the highest exposure. Eureka’s claim-level analysis and prior art landscape tools help IP teams build invalidation arguments or design-around strategies before they face the full cost of BPCIA litigation.
Run a freedom-to-operate analysis on US11459595B2 to assess your product’s exposure
Run FTO in Eureka →Similar BPCIA biosimilar patent cases in New Jersey and related federal courts
These cases involve BPCIA patent infringement actions in D.N.J. and comparable federal courts covering monoclonal antibody and biologic biosimilar products.
What Amgen v. Celltrion signals for the denosumab biosimilar IP landscape
A 29-patent Consent Judgment in under a year sets a pattern for how BPCIA disputes over Prolia® and XGEVA® biosimilars may resolve.
Patent volume signals total deterrence strategy, not just protection
Asserting 29 patents across composition, process, formulation, and purification layers is consistent with a ‘patent thicket’ enforcement strategy designed to maximize litigation cost and risk for biosimilar entrants. Companies developing or investing in denosumab biosimilars should conduct multi-layer FTO analysis across all patent families before filing an aBLA.
Consent Judgment without public terms sets a template — but not a precedent
Because no validity or infringement ruling was issued, no patent in the 29-patent portfolio was publicly invalidated or found not infringed. Each subsequent biosimilar challenger must relitigate from scratch. The settlement creates a business precedent for negotiated entry but provides zero legal shelter for other applicants seeking to design around or invalidate these patents.
Amgen v Celltrion — key questions answered
Amgen asserted 29 US patents covering denosumab (Prolia® and XGEVA®) including US11459595B2, US7427659B2, US11299760B2, and 26 further patents spanning antibody composition, cell culture manufacturing, purification processes, and drug formulation. The case was filed in the District of New Jersey on 28 May 2024.
A Consent Judgment closes the litigation through a negotiated court-entered order rather than a merits ruling. In BPCIA cases it typically accompanies a private settlement specifying when Celltrion may commercially launch its denosumab biosimilar in the US. The specific launch date and any royalty terms are not publicly disclosed in the available case record.
No. The case closed via Consent Judgment without any court ruling on patent validity or infringement. All 29 asserted patents remain formally unchallenged on the merits in this proceeding. Other biosimilar developers cannot rely on this case to clear the patent landscape for their own denosumab products.
The Consent Judgment binds only the named parties — Amgen, Amgen Manufacturing Limited LLC, Celltrion Inc., and Celltrion USA Inc. Other biosimilar applicants who have filed or plan to file an aBLA for a denosumab biosimilar face the full force of Amgen’s 29-patent portfolio and must independently negotiate or litigate their own market-entry rights.
The 310-day timeline suggests commercial settlement momentum prevailed over full litigation of a complex 29-patent dispute. BPCIA cases involving multiple patent families frequently settle before claim construction to avoid costly and uncertain multi-year litigation. The active confidentiality order dispute noted in the docket suggests vigorous pre-settlement contest, but the specific driver of early resolution is not disclosed in the public record.
PatSnap Eureka searches patents and litigation data to answer instantly.